NEW YORK – A gene therapy using lentiviral particles to generate CAR T cells inside multiple myeloma patients has shown the ability to eliminate the small number of cancer cells in the bone marrow ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Writing in JAMA, regulators said randomized controlled trials with a survival or time-to-event endpoint would be expected for approval of a new CAR T-cell therapy.

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.

Studies presented at the American Society of Hematology's annual meeting investigated the use of circulating tumor cells to assess the risk of progression in multiple myeloma patients.

The firm plans to seek accelerated approval from the FDA next year, while it launches a Phase III trial to support other regulatory applications.

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Of the 11 patients treated with BE-CAR7 T cells, seven are in remission, including one patient who has been in remission for three years.

Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely enables them to hide from immune attack.

Researchers at ASH shared Phase III data comparing the pre- and five-year post-treatment adjusted annualized bleeding rates, ...

The firm said it is planning a regulatory filing with the European Medicines Agency next year to begin clinical studies of PCT1:CO-STIM.